<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:content="http://purl.org/rss/1.0/modules/content/" version="2.0">
  <channel>
    <title><![CDATA[Skin Cancer]]></title>
    <link>https://www.leadingmarketresearch.com/pharmaceuticals-biotechnology/pharmaceuticals/therapeutic-areas/cancer/skin-cancer</link>
    <description><![CDATA[Skin Cancer]]></description>
    <pubDate>Mon, 22 Jun 2026 17:55:02 +0000</pubDate>
    <generator>Zend_Feed</generator>
    <docs>http://blogs.law.harvard.edu/tech/rss</docs>
    <item>
      <title><![CDATA[Epiomic Epidemiology Series: Malignant Melanoma Forecast in 20 Major Markets 2016-2026]]></title>
      <link>https://www.leadingmarketresearch.com/epiomic-epidemiology-series-malignant-melanoma-forecast-in-20-major-market</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;">Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Malignant Melanoma in 20 Major Markets
Cutaneous Malignant Melanoma is a form of cancer of the skin arising from melanocytes on the external surface of the skin. It can occur anywhere on the body and is more aggressive than the other two forms of skin cancer (basal cell and squamous cell non-melanoma cell skin cancer). Melanoma is the result of a combination of genetic / phenotypic predisposition and environmental catalysts. 
This report provides the current incident population for Malignant Melanoma across 20 Major Markets (USA, France, Germany, Italy, Spain, UK, Sweden, Norway, Japan, China, Russia, Australia, Canada, Turkey, South Africa, Saudi Arabia, South Korea, Argentina, Brazil and Mexico) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity. 
Providing a value-added level of insight from the analysis team at Black Swan, several of ...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-185471"><span class="price">$6,400.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Thu, 06 Oct 2016 11:26:22 +0000</pubDate>
    </item>
    <item>
      <title><![CDATA[Epiomic Epidemiology Series: Non-Melanoma Skin Cancer Forecast in 8 Major Markets 2016-2026]]></title>
      <link>https://www.leadingmarketresearch.com/epiomic-epidemiology-series-non-melanoma-skin-cancer-forecast-in-8-major-m</link>
      <description><![CDATA[<table><tr><td  style="text-decoration:none;">Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Non-Melanoma Skin Cancer in 8 Major Markets
Non-melanoma skin cancer (NMSC) is cancer of the skin not arising from melanocytes. It is one of the most frequently occurring cancers, although it tends not to be reported via registries as prognosis for patients is good in most cases. 
There are two main types of NMSC malignancies; Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC). BCC is the more predominant type and are a heterogeneous group of tumours ranging from superficial to deeply invasive tumours than can be life threatening.

This report provides the current prevalent population for Non-melanoma skin cancer across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity. 
Providing a value-added level of insight from the analysis team at Black Swan, se...





        
    <div class="price-box">
                                                            <span class="regular-price" id="product-price-185479"><span class="price">$6,400.00</span></span>
                        
        </div>

</td></tr></table>]]></description>
      <pubDate>Thu, 06 Oct 2016 11:26:22 +0000</pubDate>
    </item>
  </channel>
</rss>
